Sensyne Health PLC (LON:SENS) has inked a strategic research agreement with the Royal Devon and Exeter NHS Foundation Trust (RD&E) that gives it secure access to 1.2mln patient records.
It is the latest in a series of similar deals with trusts that will ultimately see the company deploy its ethical AI to improve patient care and accelerate research into new medicines.
RD&E will receive investment of £250,000 over five years and just over 1.4mln Sensyne shares.
In the same announcement, Sensyne said similar agreements with George Eliot Hospital Trust and Wye Valley Trust, announced in January 2019, have now received NHS England approval.
Together with the new RD&E agreement, this brings the combined total of anonymised data available for analysis by Sensyne up from 6.8mln to 8.5mln patients.